{"title":"[Antithrombotic therapy in acute coronary syndrome].","authors":"Andreas Schäfer","doi":"10.1055/a-2171-6892","DOIUrl":null,"url":null,"abstract":"Dual antiplatelet therapy (DAPT) is the cornerstone of maintenance medication following acute coronary syndromes (ST elevation myocardial infarction, non-ST elevation myocardial infarction, unstable angina). Over the last decade, P2Y12 inhibition in addition to low-dose acetylsalicylic acid has been intensively debated. In patients with acute coronary syndromes, balancing the reduction in cardiovascular events and increase in major bleeding during treatment with more potent P2Y12 inhibitors such as prasugrel and ticagrelor is still an issue. A special focus is on patients already treated with oral anticoagulants for stroke prevention in atrial fibrillation who require additional platelet inhibition following coronary stenting. This article summarizes the major recommendations given in the most recent Guideline for \"Acute Coronary Syndromes\" published by the European Society of Cardiology (ESC). The recommendations finally address strategies to reduce an increased bleeding risk based on clinical predictors.","PeriodicalId":11370,"journal":{"name":"Deutsche Medizinische Wochenschrift","volume":null,"pages":null},"PeriodicalIF":0.6000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Deutsche Medizinische Wochenschrift","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2171-6892","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Dual antiplatelet therapy (DAPT) is the cornerstone of maintenance medication following acute coronary syndromes (ST elevation myocardial infarction, non-ST elevation myocardial infarction, unstable angina). Over the last decade, P2Y12 inhibition in addition to low-dose acetylsalicylic acid has been intensively debated. In patients with acute coronary syndromes, balancing the reduction in cardiovascular events and increase in major bleeding during treatment with more potent P2Y12 inhibitors such as prasugrel and ticagrelor is still an issue. A special focus is on patients already treated with oral anticoagulants for stroke prevention in atrial fibrillation who require additional platelet inhibition following coronary stenting. This article summarizes the major recommendations given in the most recent Guideline for "Acute Coronary Syndromes" published by the European Society of Cardiology (ESC). The recommendations finally address strategies to reduce an increased bleeding risk based on clinical predictors.
期刊介绍:
Ein Schwerpunktthema - verschiedene Perspektiven
Mit vielen praktischen Tipps und konkreten Handlungsanweisungen.
Kurz und prägnant: Aktuell informiert
Interessante Nachrichten für Sie zusammengefasst und von Experten kommentiert.
Fundiertes Fachwissen - für Einsteiger und Profis
Ein bunter Mix aus Übersichten, Fallbeispielen, Kasuistiken und Schritt-für-Schritt-Anleitungen.
Blick über den Tellerrand
Erweitern Sie Ihren Fokus über das reine Fachwissen hinaus mit "Medizin im Kontext".